Florian Eisele

Wuerzburg, BY, Germany

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 31 publications

Second-line treatment with tafasitamab and lenalidomide for relapsed/refractory primary cutaneous diffuse large B-cell lymphoma.

Second-line treatment with tafasitamab and lenalidomide for relapsed/refractory primary cutaneous diffuse large B-cell lymphoma.

Journal: Leukemia & lymphoma

Published: May 22, 2026

Significant burden of low-grade infections in patients treated with T-cell-engaging therapies for Multiple Myeloma.

Significant burden of low-grade infections in patients treated with T-cell-engaging therapies for Multiple Myeloma.

Journal: Blood advances

Published: August 11, 2025

Significant burden of low-grade infections in patients treated with T-cell-engaging therapies for multiple myeloma.

Significant burden of low-grade infections in patients treated with T-cell-engaging therapies for multiple myeloma.

Journal: Blood advances

Published: August 11, 2025

Endothelial dysfunction and proinflammatory state determine severe hematotoxicity and inferior outcome of CAR-T therapy.

Endothelial dysfunction and proinflammatory state determine severe hematotoxicity and inferior outcome of CAR-T therapy.

Journal: HemaSphere

Published: August 06, 2025

Correction to: Azacitidine in combination with shortened venetoclax treatment cycles in patients with acute myeloid leukemia.

Correction to: Azacitidine in combination with shortened venetoclax treatment cycles in patients with acute myeloid leukemia.

Journal: Annals of hematology

Published: November 19, 2024

Azacitidine in combination with shortened venetoclax treatment cycles in patients with acute myeloid leukemia.

Azacitidine in combination with shortened venetoclax treatment cycles in patients with acute myeloid leukemia.

Journal: Annals of hematology

Published: August 18, 2024

Comparison of T cell response to vaccination in rheumatic patients treated with Janus kinase inhibitors and TNF inhibitors.

Comparison of T cell response to vaccination in rheumatic patients treated with Janus kinase inhibitors and TNF inhibitors.

Journal: BMC rheumatology

Published: July 06, 2024

Changes in T-cell subsets, preexisting cytopenias and hyperferritinaemia correlate with cytopenias after BCMA targeted CAR T-cell therapy in relapsed/refractory multiple myeloma: Results from a prospective comprehensive biomarker study.

Changes in T-cell subsets, preexisting cytopenias and hyperferritinaemia correlate with cytopenias after BCMA targeted CAR T-cell therapy in relapsed/refractory multiple myeloma: Results from a prospective comprehensive biomarker study.

Journal: British journal of haematology

Published: March 18, 2024

Dismal prognosis of Pneumocystis jirovecii pneumonia in patients with multiple myeloma.

Dismal prognosis of Pneumocystis jirovecii pneumonia in patients with multiple myeloma.

Journal: Annals of hematology

Published: September 04, 2023

Sequential antigen loss and branching evolution in lymphoma after CD19- and CD20-targeted T-cell-redirecting therapy.

Sequential antigen loss and branching evolution in lymphoma after CD19- and CD20-targeted T-cell-redirecting therapy.

Journal: Blood

Published: June 28, 2023

Venetoclax salvage therapy in relapsed/refractory multiple myeloma.

Venetoclax salvage therapy in relapsed/refractory multiple myeloma.

Journal: Haematologica

Published: May 07, 2023

Functionally Defective T Cells After Chemotherapy of B-Cell Malignancies Can Be Activated by the Tetravalent Bispecific CD19/CD3 Antibody AFM11.

Functionally Defective T Cells After Chemotherapy of B-Cell Malignancies Can Be Activated by the Tetravalent Bispecific CD19/CD3 Antibody AFM11.

Journal: Journal of immunotherapy (Hagerstown, Md. : 1997)

Published: May 16, 2019

Showing 1-12 of 31

Last Updated: 09/26/2026